ARGX
argenx NV ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$46.44B
P/E Ratio
38.25
EPS
$19.56
Beta
-0.09
52W High
$934.62
52W Low
$510.06
50-Day MA
$772.97
200-Day MA
$756.87
Dividend Yield
—
Profit Margin
30.50%
Forward P/E
28.09
PEG Ratio
1.19
About argenx NV ADR
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Fundamentals
| Revenue (TTM) | $4.24B |
| Gross Profit (TTM) | $2.42B |
| EBITDA | $1.06B |
| Operating Margin | 27.40% |
| Return on Equity | 20.20% |
| Return on Assets | 8.86% |
| Revenue/Share (TTM) | $2.77 |
| Book Value | $118.34 |
| Price-to-Book | 6.33 |
| Price-to-Sales (TTM) | 10.96 |
| EV/Revenue | 10.15 |
| EV/EBITDA | 32.16 |
| Quarterly Earnings Growth (YoY) | -31.90% |
| Quarterly Revenue Growth (YoY) | 73.00% |
| Shares Outstanding | $62.06M |
| Float | $61.98M |
| % Insiders | 0.01% |
| % Institutions | 48.96% |
Analyst Ratings
Consensus ($1019.61 target)
5
Strong Buy15
Buy3
HoldData last updated: 4/7/2026